New drug trial aims to rescue failing lungs after transplant

NCT ID NCT07538336

Not yet recruiting Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a one-time infusion of emapalumab in 40 adults who had a lung transplant and now have a sudden drop in lung function (acute lung allograft dysfunction). The goal is to see if the drug can help their lungs recover to near-normal function within 90 days. Emapalumab blocks a protein that may be causing the damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: emapalumab
What this could lead to: If it works, this could point toward a treatment for sudden lung function decline after lung transplant, helping patients breathe better without needing a new transplant.
What could go wrong: This is a small, early-phase trial with only 40 people. The drug may not improve lung function, and there are risks like serious infections since emapalumab suppresses the immune system.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG TRANSPLANT

Contacts and locations

Locations

University of California, Los Angeles

Los Angeles, California, 90095, United States
University of California, San Francisco

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.